|
|
|
Volumn 3, Issue 8, 2011, Pages 923-924
|
|
DIAPREV-IT study of diabetes therapy Diamyd® receives further funding and will continue despite disappointing Phase III trial results.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AUTOANTIGEN;
GLUTAMATE DECARBOXYLASE;
GLUTAMATE DECARBOXYLASE 2;
ANIMAL;
CHILD;
DISEASE COURSE;
EUROPE;
FINANCIAL MANAGEMENT;
HUMAN;
IMMUNOLOGY;
INSULIN DEPENDENT DIABETES MELLITUS;
NOTE;
PHASE 3 CLINICAL TRIAL (TOPIC);
TREATMENT OUTCOME;
VACCINATION;
ANIMALS;
AUTOANTIGENS;
CHILD;
CLINICAL TRIALS, PHASE III AS TOPIC;
DIABETES MELLITUS, TYPE 1;
DISEASE PROGRESSION;
EUROPE;
FINANCIAL SUPPORT;
GLUTAMATE DECARBOXYLASE;
HUMANS;
TREATMENT OUTCOME;
VACCINATION;
|
|
EID: 84856402593
PISSN: None
EISSN: 17507448
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (4)
|
|
References (0)
|